The Archer® FusionPlex Sarcoma panel is a targeted sequencing test to simultaneously detect and identify fusions of 26 genes associated with soft tissue cancers. Using Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment, fusions of all genes in this panel can be identified in a single sequencing test, even without prior knowledge of fusion partners or breakpoints.
Key Features

Identify multiple sarcoma-related fusions in a single assay.


Identify novel fusion partners and fusion breakpoints.


Characterize fusion partners at single-nucleotide resolution.


Reduce turn-around time and eliminate reflex testing.

Specifications and Performance


Gene Targets

> 10ng

Input Nucleic Acid Required*

> 95%

Unique Molecular On-Target %

2.5 hours

Hands-on Time

9 hours

Total Time

Illumina and
Ion Torrent


Fresh Frozen or FFPE

Sample Types

*Input recommendations for FFPE samples vary depending on Archer PreSeq® RNA QC score; 50ng input recommended in absence of PreSeq screening

Detecting fusions using the Archer FusionPlex Sarcoma Panel

ArcherDX, Inc. has developed a panel for the rapid detection of sarcoma-associated translocations from total nucleic acid isolated from tumor samples—including FFPE preserved specimens. Anchored Multiplex PCR (AMP) enables rapid preparation of highly multiplexed next-generation sequencing (NGS) libraries for targeted capture of mRNAs produced from fusion genes. The Archer technology permits the simultaneous detection of both known recurrent fusions as well as previously unidentified fusions at key breakpoints in target genes. Archer’s Sarcoma panel offers a complete fusion detection solution, from library preparation through data analysis, for both the Illumina and Ion Torrent platforms.

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.